VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials

doi:10.2196/resprot.7016

JMIR Publications

JMIR Research Protocols

Browse by Year:

Browse:
Issues
Authors
Themes

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.

JMIR Research Protocols

Published on 15.02.17 in Vol 6, No 2 (2017): February

This paper is in the following e-collection/theme issue:

Tweetations for "VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials"

Val Gebski, Emma Gibbs, Mihir Gandhi, Gilles Chatellier, Aurelia Dinut, Helena Pereira, Pierce KH Chow, Valérie Vilgrain

JMIR Res Protoc 2017 (Feb 15); 6(2):e17

Tweets 1 - 3 of 3.

Tweets 1 - 3 of 3. 1

JMIR Research Protocols

Citing this Article

Published on 15.02.17 in Vol 6, No 2 (2017): February

This paper is in the following e-collection/theme issue:

Tweetations for "VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials"

Tweets 1 - 3 of 3.